Endoscopic findings and outcomes of gastric mucosal changes relating to potassium‐competitive acid blocker and proton pump inhibitor therapy [PDF]
DEN OpenGastric mucosal changes associated with long‐term potassium‐competitive acid blocker and proton pump inhibitor (PPI) therapy may raise concern. In contrast to that for PPIs, the evidence concerning the safety of long‐term potassium‐competitive acid ...
Satoshi Shinozaki +8 more
doaj +3 more sources
Potassium‐Competitive Acid Blocker‐Associated Gastric Hyperplastic Polyps With Severe Bleeding: A Case Series [PDF]
DEN OpenGastric hyperplastic polyps can cause gastrointestinal bleeding, and their enlargement has been associated with long‐term acid‐suppressive therapy. Vonoprazan (VPZ), a potassium‐competitive acid blocker, provides potent acid suppression and may induce ...
Kengo Kasuga +9 more
doaj +2 more sources
Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. [PDF]
J Neurogastroenterol Motil, 2018 Potassium-competitive acid blockers are expected to be the next generation of drugs for the treatment of diseases caused by gastric acid. In 2015, vonoprazan fumarate, a novel potassium-competitive acid blocker, was approved by the Japanese health insurance system.
Masaoka T +7 more
europepmc +4 more sources
Potassium-competitive Acid Blocker-based Therapy for Helicobacter pylori Eradication
The Korean Journal of Gastroenterology, 2017 Article: Vonoprazan, a Novel Potassium-competitive Acid Blocker, as a Component of First-line and Second-line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-blind ...
Chang Seok Bang, Gwang Ho Baik
doaj +2 more sources
The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study [PDF]
The Korean Journal of Helicobacter and Upper Gastrointestinal ResearchObjectives A significant number of patients with gastroesophageal reflux disease (GERD) experience refractory symptoms despite conventional doses of a proton pump inhibitor (PPI).
Na Rae Lim, Woo Chul Chung
doaj +2 more sources
Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication? [PDF]
Gut and Liver, 2021 Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used for Helicobacter pylori eradication in Japan. To date, many studies, as well as several systematic reviews and meta-analyses (MAs), have compared VPZ-based 7-day ...
Soichiro Sue, Shin Maeda
doaj +2 more sources
Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept [PDF]
Research, 2022 Conventional methods of drug design require compromise in the form of side effects to achieve sufficient efficacy because targeting drugs to specific organs remains challenging.
Ming-Shu Wang +7 more
doaj +2 more sources
JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases [PDF]
Pharmacology Research & Perspectives, 2023 The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long‐term or lifetime administration; thus ...
Jin Mo Ku +7 more
doaj +2 more sources
Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects [PDF]
Clinical and Translational Science, 2023 Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and pharmacodynamics (PDs) of multiple doses of keverprazan.
Sufeng Zhou +8 more
doaj +2 more sources
Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan [PDF]
Journal of General and Family Medicine, 2021 Introduction Gastroesophageal reflux disease is a common condition, and proton pump inhibitors (PPIs) are the mainstays of treatment. However, concerns have been raised about the safety of PPIs.
Yasuki Habu +5 more
doaj +2 more sources